In Silico Identification of Key Genes and Immune Infiltration Characteristics in Epicardial Adipose Tissue from Patients with Coronary Artery Disease
Source check: Source checked. Not independent scientific confirmation.
Finding: LASSO and SVM-RFE selected TCF21, CDH19, XG and NNAT as coronary-artery-disease-associated genes in epicardial adipose-tissue expression data; associations were checked in two additional GEO datasets. Immune-cell estimates are computational, and no experimental perturbation validates the proposed biology.
Technology: LASSO and SVM-RFE select coronary-disease feature genes from expression datasets; CIBERSORT estimates immune-cell infiltration.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- LASSO and SVM-RFE select coronary-disease feature genes from expression datasets; CIBERSORT estimates immune-cell infiltration.
- Test and result
- LASSO and SVM-RFE selected TCF21, CDH19, XG and NNAT as coronary-artery-disease-associated genes in epicardial adipose-tissue expression data; associations were checked in two additional GEO datasets
- Limitation / still unknown
- Immune-cell estimates are computational, and no experimental perturbation validates the proposed biology.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9637040/ · https://pubmed.ncbi.nlm.nih.gov/36345357/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.